ARS Pharmaceuticals, Inc
$ 8.18
0.00%
17 Apr - close price
- Market Cap 812,252,000 USD
- Current Price $ 8.18
- High / Low $ 8.35 / 8.05
- Stock P/E N/A
- Book Value 1.15
- EPS -1.74
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.33 %
- ROE -0.92 %
- 52 Week High 18.90
- 52 Week Low 6.66
About
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine aerosol with absorption technology for patients and their families at risk of severe allergic reactions to food, medication, and insect stings. The company is headquartered in San Diego, California.
Analyst Target Price
$26.71
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-19 | 2025-11-10 | 2025-08-13 | 2025-05-07 | 2025-03-19 | 2024-11-07 | 2024-08-06 | 2024-05-09 | 2024-03-21 | 2023-11-09 | 2023-08-10 | 2023-05-15 |
| Reported EPS | -0.42 | -0.52 | -0.46 | -0.35 | 0.51 | -0.2 | -0.13 | -0.11 | -0.07 | -0.16 | -0.18 | -0.16 |
| Estimated EPS | -0.4246 | -0.46 | -0.46 | -0.11 | -0.1175 | -0.15 | -0.12 | -0.11 | -0.14 | -0.18 | -0.17 | -0.17 |
| Surprise | 0.0046 | -0.06 | 0 | -0.24 | 0.6275 | -0.05 | -0.01 | 0 | 0.07 | 0.02 | -0.01 | 0.01 |
| Surprise Percentage | 1.0834% | -13.0435% | 0% | -218.1818% | 534.0426% | -33.3333% | -8.3333% | 0% | 50% | 11.1111% | -5.8824% | 5.8824% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.5 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SPRY
2026-04-17 15:40:51
The FDA has approved an expanded use for ARS Pharmaceuticals' needle-free epinephrine nasal spray, neffy 1 mg, eliminating prior age restrictions for emergency treatment of severe allergic reactions. The updated guidance allows use for patients weighing at least 33 pounds and provides new storage and handling instructions. Northland initiated coverage with an outperform rating and a $25 price target, viewing the nasal spray as a significant innovation.
2026-04-15 20:09:08
Health Canada has approved neffy 2 mg (epinephrine nasal spray) for the emergency treatment of allergic reactions in adults and children weighing 30 kg or more, making it the first needle-free epinephrine treatment available in Canada. This approval, following a similar clearance in China, is a significant advancement for patients at risk of anaphylaxis, offering a convenient and timely treatment option. ARS Pharmaceuticals, developer of neffy, expects the product to be available in Canada in summer 2026 through its licensing agreement with ALK-Abelló A/S.
2026-04-15 09:39:57
ARS Pharmaceuticals (Nasdaq: SPRY) has announced that Health Canada has approved neffy 2 mg (epinephrine nasal spray) for the emergency treatment of allergic reactions in adults and children weighing 30 kg or more. This marks the first needle-free epinephrine option for Canada, with availability expected in summer 2026 through a partnership with ALK Canada. ARS Pharma has received $155 million in upfront and milestone payments and is eligible for additional payments and royalties.
2026-04-10 10:09:08
Analysts have issued a consensus "Hold" rating for ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), with an average one-year price target of $28.25. The company's shares recently traded at $8.14, reflecting a market capitalization of $808 million, and it reported EPS of -$0.42, which met estimates, alongside revenues surpassing expectations. Institutional investors have notably increased their holdings in the company.
2026-04-09 20:09:43
Northland initiated coverage on ARS Pharmaceuticals Inc (NASDAQ:SPRY) with an Outperform rating and a $25.00 price target, highlighting the potential of its neffy product, a needle-free intranasal epinephrine treatment. The firm anticipates neffy will achieve U.S. peak sales exceeding $1 billion due to expected improvements in market access and adoption from new and existing users. This positive outlook follows ARS Pharmaceuticals' strong Q4 2025 earnings and a recent FDA label update removing an age restriction for neffy.
2026-04-09 07:39:32
The article provides a financial overview of ARS Pharmaceuticals Inc (SPRY), detailing its revenue breakdown, profitability margins, and a comparison with competitors. SPRY maintains a gross margin of 78.09% but reports negative operating and net margins, as well as a negative Return on Equity. The company has a market capitalization of $821.19M and is benchmarked against industry leaders TBPH and EVO.
